Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Inclusion Criteria

• •1. Age \>/=15 years.
• •2. Written informed consent.
• •3. Patients with chronic lymphoid malignancies that are either refractory to frontline therapy or have relapsed and that have a predicted probability of response of less than 20% with conventional therapy or allogeneic/autologous stem cell transplantation.
• •4. The following histologies are included: B-cell chronic lymphocytic leukemia (B-CLL or B-cell CLL), B-cell prolymphocytic leukemia (PLL), chronic lymphoid leukemia (CLL/PLL), hairy cell leukemia and hairy cell variant, mantle cell leukemia/lymphoma, marginal zone lymphoma/leukemia, splenic lymphoma with villous lymphocytes, CLL with evidence of transformation (e.g., Richter's transformation), large granular lymphocytic leukemia (LGL and NK-cell type).
• •5. Patients with above mentioned histologies whose malignant cell population have expressed both CD52 and CD20 in \>/= 20% of cells as assessed by flow cytometry or immunohistochemistry. Expression of CD20 or CD52 \< 20% is permitted if patients received rituximab or alemtuzumab, respectively, within 3 months prior to study start.